A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer
, , , , , , e | 03 mar 2019
INFORMAZIONI SU QUESTO ARTICOLO
Article Category: Review
Pubblicato online: 03 mar 2019
Pagine: 6 - 14
Ricevuto: 31 ago 2018
Accettato: 05 gen 2019
DOI: https://doi.org/10.2478/raon-2019-0006
© 2019 Li Ma, Yu Men, Lingling Feng, Jingjing Kang, Xin Sun, Meng Yuan, Wei Jiang, Zhouguang Hui published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Background
The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy. Loco-regional recurrence constitutes the predominant failure patterns. Previous studies confirmed the relationship between increased biological equivalent doses and improved overall survival. However, the large randomized phase III study, RTOG 0617, failed to demonstrate the benefit of dose-escalation to 74 Gy compared with 60 Gy by simply increasing fraction numbers.
Conclusions
Though effective dose-escalation methods have been explored, including altered fractionation, adapting individualized increments for different patients, and adopting new technologies and new equipment such as new radiation therapy, no consensus has been achieved yet.